Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study
Journal of Allergy and Clinical Immunology · 2024
DOI: 10.1016/j.jaci.2024.08.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024. Verfasst von Christo Tsilifis und 29 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Haematopoietic Stem Cell Transplant Unit, Great North Children's Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, …. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, CTLA-4 Antigen. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, UCLH Biomedical Research Centre.
Abstract (Originalsprache)
BACKGROUND: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) insufficiency causes a primary immune regulatory disorder characterized by lymphoproliferation, dysgammaglobulinemia, and multiorgan autoimmunity including cytopenias and colitis. OBJECTIVE: We examined the outcome of hematopoietic stem cell transplantation (HSCT) for CTLA-4 insufficiency and study the impact of pre-HSCT CTLA-4 fusion protein (CTLA-4-Ig) therapy and pre-HSCT immune dysregulation on survival and immunologic outcome. METHODS: This was a retrospective study of HSCT for CTLA-4 insufficiency and 2q33.2-3 deletion from the European Society for Blood and Marrow Transplantation Inborn Errors Working Party. Primary end points were overall survival (OS) and disease- and chronic graft-versus-host disease-free survival (DFS). Secondary end point was immunologic outcome assessed by immune dysregulation disease activity (IDDA) score. RESULTS: Forty patients were included over a 25-year period. Before HSCT, 60% received CTLA-4-Ig, and median (range) IDDA score was 23.3 (3.9-84.0). Median (range) age at HSCT was 14.2 (1.3-56.0) years. Patients received peripheral blood stem cell (58%) or marrow (43%) from a matched unrelated donor (75%), mismatched unrelated donor (12.5%), or matched family donor (12.5%). Median (range) follow-up was 3 (0.6-15) years, and 3-year OS was 76.7% (58-87%) and DFS was 74.4% (54.9-86.0%). At latest follow-up, disease of 28 of 30 surviving patients was in disease-free remission with median IDDA reduction of 16. Probability of OS and DFS was greater in patients with lower disease activity before HSCT (IDDA < 23, P = .002 and P = .006, respectively). CTLA-4-Ig receipt did not influence OS or DFS. Cause of death was transplant related in 7 of 8 patients. CONCLUSION: HSCT is an effective therapy to prevent ongoing disease progression and morbidity, with improving survival rates over time and in patients with lower pre-HSCT disease activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paediatric Haematopoietic Stem Cell Transplant Unit, Great North Children's Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; Translational and Clinical Research Institute, Newcast…
- Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Department of Pediatrics and Adolescent Medicine, Division of Pe…
- UCL Institute of Immunity and Transplantation, UCL, London, The Netherlands; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
- Bone Marrow Transplant Unit, Oncology Service, Hospital Sant Joan de Déu, Barcelona, Spain.
- Paediatric Haematopoietic Stem Cell Transplant Unit, University Hospital La Paz, Madrid, Spain.
- Paediatric Stem Cell Transplantation, Royal Hospital for Children, Glasgow, United Kingdom.
Förderung
- National Institute for Health and Care Research
- UCLH Biomedical Research Centre
Zitieren
APA
Tsilifis, C., Speckmann, C., Lum, S. H., Fox, T. A., Soler, A. M., Mozo, Y., Corral, D., Ewins, A. M., Hague, R., Oikonomopoulou, C., Kałwak, K., Drabko, K., Wynn, R., Morris, E. C., Elcombe, S., Bigley, V., Lougaris, V., Malagola, M., Hauck, F., …, & Slatter, M. A. (2024). Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2024.08.020
Vancouver
Tsilifis C, Speckmann C, Lum SH, Fox TA, Soler AM, Mozo Y, et al. Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study. Journal of Allergy and Clinical Immunology. 2024. doi:10.1016/j.jaci.2024.08.020
BibTeX
@article{Tsilifis2024,
author = {Tsilifis, Christo and Speckmann, Carsten and Lum, Su Han and Fox, Thomas A and Soler, Adriana Margarit and Mozo, Yasmina and Corral, Dolores and Ewins, Anna-Maria and Hague, Rosie and Oikonomopoulou, Christina and Kałwak, Krzysztof and Drabko, Katarzyna and Wynn, Robert and Morris, Emma C and Elcombe, Suzanne and Bigley, Venetia and Lougaris, Vassilios and Malagola, Michele and Hauck, Fabian and Sedlacek, Petr and Laberko, Alexandra and Tjon, Jennifer M L and Buddingh, Emilie P and Wehr, Claudia and Grimbacher, Bodo and Gennery, Andrew R and Lankester, Arjan C and Albert, Michael H and Neven, Bénédicte and Slatter, Mary A},
title = {Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study},
journal = {Journal of Allergy and Clinical Immunology},
year = {2024},
doi = {10.1016/j.jaci.2024.08.020}
}
EUVIMED